Sally Amanuel is Chief Commercial Officer (CCO) of Ergomed Group, leading the unified Commercial, Sales, and Marketing functions to deliver an integrated go-to-market strategy and enhanced client engagement.
With an extensive background spanning regulatory affairs, clinical delivery, and client engagement, Sally brings deep expertise across pharmacovigilance and CRO operations. She has held senior leadership roles at PrimeVigilance, Ergomed CRO, and Worldwide Clinical Trials, as well as at global biopharmaceutical organizations including Biogen, Pfizer, and GSK.
Throughout her career, Sally is known for her collaborative leadership style and her focus on aligning commercial strategy with operational excellence and client needs. At Ergomed, Sally is responsible for unifying Commercial, Sales, and Marketing under a single strategic vision, strengthening client relationships, and supporting sustainable, long-term growth. She is a staunch advocate of transparency, quality, and continuous improvement.
Sally holds a Master’s degree in Biotechnological Law and Ethics from the University of Sheffield and an MBA from the University of Liverpool, UK.
